Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Zameel Cader of the Nuffield Department of Clinical Neurosciences will use MRC Technology’s commercialization services to advance new treatments for migraine pain control.

MRC Technology, a technology transfer organisation, is collaborating with Dr Zameel Cader to screen selective and potent potassium channel activators to develop novel therapeutic interventions in migraine. Drawing on MRC Technology’s commercialisation expertise in drug discovery, the project focuses on bringing to clinic more effective pain treatments arising from the work of Dr Cader’s group in identifying KCNK18, the first gene underlying typical migraine.

KCNK18 encodes a tandem-pore background potassium channel, TRESK, which is linked to causing migraines and controls the sensitivity of pain nerves in the brain. If TRESK is faulty or inactive, the body’s threshold to pain can be significantly lowered. Migraine is the most common neurological disorder, with prevalence estimated at 18.2% in females and 6.5% in males, and is characterised by a severe, recurring headache, often accompanied by nausea, vomiting and increased sensitivity to light and sound.

Dr Justin Bryans at MRC Technology, said: 'We are delighted to be working with Dr Cader and his team who have made such a significant discovery in the underlying causes of migraine. We are hopeful that our collaboration will lead to treatments that could not only prevent migraines, but could potentially result in a more general pain therapy with even wider impact.'

'Migraine is a major cause of disability worldwide and it has been estimated to be the most costly neurological disorder in Europe', commented Dr Cader. 'We have made a major step forward in our understanding of why people suffer with migraine and with MRC Technology’s wealth of drug discovery experience, we look forward to working with them to bring novel treatments to market.'

Read more information from ScienceDirect

photo credit: tudedude via photopin cc

Similar stories

Attention and memory deficits persist for months after recovery from mild COVID

Researchers from Oxford’s Nuffield Department of Clinical Neurosciences and Department of Experimental Psychology have shown that people who have had COVID but don’t complain of long COVID symptoms in daily life nevertheless can show degraded attention and memory for up to six to nine months.

New spinout company: Human-Centric Drug Discovery

Human-Centric Drug Discovery is a new Oxford University spinout company from Professor Zameel Cader's lab.

Funding received for research into Motor Neuron Disease

A £210,000 donation from the Alan Davidson Foundation has been made to our Department to advance our world-leading research into Motor Neuron Disease. The funding will support a project manager to deliver an innovative research project using the genetic causes of MND to develop approaches to early diagnosis.

Protein test could lead to earlier and better diagnosis of Parkinson’s

Scientists have observed the clumping of alpha-synuclein in the cerebrospinal fluid taken from people with Parkinson's. The findings offer hope that a pioneering new clinical test could be developed to diagnose Parkinson's correctly in its early stages.

Evaluating risk to people with epilepsy during the COVID-19 pandemic - study wins international prize

In May 2020 our researchers initiated a global project to investigate how COVID-19 has affected people with epilepsy, their carers and health care workers.